1. Home
  2. TRAK vs MOLN Comparison

TRAK vs MOLN Comparison

Compare TRAK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$8.64

Market Cap

157.2M

Sector

Technology

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.93

Market Cap

154.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
MOLN
Founded
1990
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
157.2M
154.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
TRAK
MOLN
Price
$8.64
$3.93
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
51.4K
5.2K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
0.90%
N/A
EPS Growth
20.69
N/A
EPS
0.28
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
N/A
Revenue Next Year
$10.04
$374.07
P/E Ratio
$30.86
N/A
Revenue Growth
4.84
N/A
52 Week Low
$6.94
$3.46
52 Week High
$18.05
$5.36

Technical Indicators

Market Signals
Indicator
TRAK
MOLN
Relative Strength Index (RSI) 48.88 48.77
Support Level $8.78 $3.65
Resistance Level $9.09 $3.96
Average True Range (ATR) 0.33 0.07
MACD 0.02 -0.01
Stochastic Oscillator 74.82 53.85

Price Performance

Historical Comparison
TRAK
MOLN

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: